Biblio

Export 2216 results:
Author Title Type [ Year(Asc)]
Filters: First Letter Of Keyword is A  [Clear All Filters]
2022
E. Lacorte, Ancidoni, A., Zaccaria, V., Remoli, G., Tariciotti, L., Bellomo, G., Sciancalepore, F., Corbo, M., Lombardo, F. L., Bacigalupo, I., Canevelli, M., Piscopo, P., and Vanacore, N., “Safety and Efficacy of Monoclonal Antibodies for Alzheimer's Disease: A Systematic Review and Meta-Analysis of Published and Unpublished Clinical Trials.”, J Alzheimers Dis, vol. 87, no. 1, pp. 101-129, 2022.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
X. Hua, Church, K., Walker, W., L'Hostis, P., Viardot, G., Danjou, P., Hendrix, S., and Moebius, H. J., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Positive Modulator of HGF/MET, Fosgonimeton, in Healthy Volunteers and Subjects with Alzheimer's Disease: Randomized, Placebo-Controlled, Double-Blind, Phase I Clinical Trial.”, J Alzheimers Dis, vol. 86, no. 3, pp. 1399-1413, 2022.
A. Sil, Erfani, A., Lamb, N., Copland, R., Riedel, G., and Platt, B., “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
A. Sil, Erfani, A., Lamb, N., Copland, R., Riedel, G., and Platt, B., “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
A. Sil, Erfani, A., Lamb, N., Copland, R., Riedel, G., and Platt, B., “Sex Differences in Behavior and Molecular Pathology in the 5XFAD Model.”, J Alzheimers Dis, vol. 85, no. 2, pp. 755-778, 2022.
S. Hannonen, Andberg, S., Kärkkäinen, V., Rusanen, M., Lehtola, J. - M., Saari, T., Korhonen, V., Hokkanen, L., Hallikainen, M., Hänninen, T., Leinonen, V., Kaarniranta, K., Bednarik, R., and Koivisto, A. M., “Shortening of Saccades as a Possible Easy-to-Use Biomarker to Detect Risk of Alzheimer's Disease.”, J Alzheimers Dis, vol. 88, no. 2, pp. 609-618, 2022.
J. Lynn, Park, M., Ogunwale, C., and Acquaah-Mensah, G. K., “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
J. Lynn, Park, M., Ogunwale, C., and Acquaah-Mensah, G. K., “A Tale of Two Diseases: Exploring Mechanisms Linking Diabetes Mellitus with Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 485-501, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
K. Metsla, Kirss, S., Laks, K., Sildnik, G., Palgi, M., Palumaa, T., Tõugu, V., and Palumaa, P., “α-Lipoic Acid Has the Potential to Normalize Copper Metabolism, Which Is Dysregulated in Alzheimer's Disease.”, J Alzheimers Dis, vol. 85, no. 2, pp. 715-728, 2022.
2021
R. Gil and Arroyo-Anlló, E. M., “Alzheimer's Disease and Face Masks in Times of COVID-19.”, J Alzheimers Dis, vol. 79, no. 1, pp. 9-14, 2021.
C. Birkenbihl, Westwood, S., Shi, L., Nevado-Holgado, A., Westman, E., Lovestone, S., and Hofmann-Apitius, M., “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
C. Birkenbihl, Westwood, S., Shi, L., Nevado-Holgado, A., Westman, E., Lovestone, S., and Hofmann-Apitius, M., “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
C. Birkenbihl, Westwood, S., Shi, L., Nevado-Holgado, A., Westman, E., Lovestone, S., and Hofmann-Apitius, M., “ANMerge: A Comprehensive and Accessible Alzheimer's Disease Patient-Level Dataset.”, J Alzheimers Dis, vol. 79, no. 1, pp. 423-431, 2021.
J. Bastrup, Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., and Volbracht, C., “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
J. Bastrup, Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., and Volbracht, C., “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
J. Bastrup, Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., and Volbracht, C., “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
J. Bastrup, Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., and Volbracht, C., “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.
J. Bastrup, Hansen, K. H., Poulsen, T. B. G., Kastaniegaard, K., Asuni, A. A., Christensen, S., Belling, D., Helboe, L., Stensballe, A., and Volbracht, C., “Anti-Aβ Antibody Aducanumab Regulates the Proteome of Senile Plaques and Closely Surrounding Tissue in a Transgenic Mouse Model of Alzheimer's Disease.”, J Alzheimers Dis, vol. 79, no. 1, pp. 249-265, 2021.

Pages